Treating prostate cancer with anti-ErbB2 antibodies
First Claim
Patent Images
1. A method of treating androgen independent prostate cancer in a human comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2, blocks ligand activation of an ErbB receptor more effectively than humanized monoclonal antibody huMAb4D5-8 and blocks by 50% or greater binding of monoclonal antibody 2C4 (ATCC HB12697) to ErbB2.
2 Assignments
0 Petitions
Accused Products
Abstract
The present application discloses treatment of prostate cancer with anti-ErbB2 antibodies.
160 Citations
14 Claims
- 1. A method of treating androgen independent prostate cancer in a human comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2, blocks ligand activation of an ErbB receptor more effectively than humanized monoclonal antibody huMAb4D5-8 and blocks by 50% or greater binding of monoclonal antibody 2C4 (ATCC HB12697) to ErbB2.
-
9. A method of treating androgen independent prostate cancer in a human comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2, blocks ligand activation of an ErbB receptor, blocks by 50% or greater binding of monoclonal antibody 2C4 (ATCC HB12697) to ErbB2, and blocks TGF-α
- activation of mitogen activated protein kinase (MAPK).
- View Dependent Claims (10, 11, 12, 13, 14)
Specification